Impact of glycoscience in fighting Covid-19

Glycoconj J. 2020 Aug;37(4):511-512. doi: 10.1007/s10719-020-09929-9.

Authors

Roberto Adamo¹, Sandro Sonnino²

Affiliations

¹ GSK, Siena, Italy. roberto.x.adamo@gsk.com.
² Department of Medical Biotechnology and Translational Medicine, University of Milan, Milan, Italy.

No abstract available

Publication types

Editorial

MeSH terms

Betacoronavirus* / immunology
COVID-19
COVID-19 Vaccines
Coronavirus Infections / immunology
Coronavirus Infections / prevention & control*
Coronavirus Infections / therapy*
Coronavirus Infections / virology
Glycomics / methods*
Glycosylation
Host Microbial Interactions / immunology
Humans
Immune Evasion
Pandemics / prevention & control*
Pneumonia, Viral / prevention & control*
Pneumonia, Viral / therapy*
Pneumonia, Viral / virology
SARS-CoV-2
Spike Glycoprotein, Coronavirus / chemistry
Spike Glycoprotein, Coronavirus / immunology
Viral Vaccines / immunology
Viral Vaccines / pharmacology

Substances

COVID-19 Vaccines
Spike Glycoprotein, Coronavirus
Viral Vaccines
spike protein, SARS-CoV-2